Inactivated Viral Vaccines

@article{Sanders2014InactivatedVV,
  title={Inactivated Viral Vaccines},
  author={Barbara Petronella Sanders and Martin H. Koldijk and Hanneke Schuitemaker},
  journal={Vaccine Analysis: Strategies, Principles, and Control},
  year={2014},
  pages={45 - 80}
}
Inactivated vaccines have been used for over a century to induce protection against viral pathogens. This established approach of vaccine production is relatively straightforward to achieve and there is an augmented safety profile as compared to their live counterparts. Today, there are six viral pathogens for which licensed inactivated vaccines are available with many more in development. Here, we describe the principles of viral inactivation and the application of these principles to vaccine… 
Vaccine Technologies and Platforms for Infectious Diseases: Current Progress, Challenges, and Opportunities
TLDR
Recent advances in vaccine technologies and platforms are summarized focusing on their mechanisms of action, advantages, and possible drawbacks.
Longitudinal Evaluation of Humoral Immunity Following Vaccination With Six ZIKV Vaccines
TLDR
The immunogenicity and efficacy of Zika virus (ZIKV) vaccines from the lab were successfully exhibited in both murine and non-human primate models, and the two DNA vaccines tested here were not as potent as the other four vaccines at inducing longterm protective humoral immunity.
An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages
Development of an Inactivated Vaccine against SARS CoV-2
TLDR
The preclinical immunogenicity, protective efficacy, and safety evaluation of a whole-virion inactivated SARS-CoV-2 vaccine candidate (ERU coV-VAC) formulated in aluminium hydroxide was found to be highly immunogenic and elicited a strong immune response in BALB/c mice and ferret models.
Review: Development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform
TLDR
The developing COVID-19 vaccine strategies and how the nanotechnology can enhance antigen presentation and strong immunogenicity using advanced technology in nanocarrier to deliver antigens are summarized.
COVID-19 vaccine platforms: Delivering on a promise?
TLDR
This review outlines the relevant platforms for developing a vaccine for SARS-CoV-2 and discusses the advantages and disadvantages of each.
Membrane Microvesicles as Potential Vaccine Candidates
TLDR
This review focuses on the mechanisms of microvesicle biogenesis and the role ofmicrovesicles in infectious diseases, and the application ofMicrovesicles as a novel and effective vaccine delivery system.
COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response
TLDR
The major vaccine candidates based on the specific vaccine platform utilized to develop them were reviewed and the immune responses generated by these candidates in humans and preclinical models to determine vaccine safety, immunogenicity, and efficacy were discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 243 REFERENCES
Advances in the development of inactivated virus vaccines.
TLDR
The present article reviews the literature and patents related to the mechanisms used for viral inactivation, mainly chemical and physical procedures, including the novel strategies that are currently being explored and that have been recently patent protected.
Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine.
  • F. André
  • Biology, Medicine
    The Journal of infectious diseases
  • 1995
TLDR
A formaldehyde-inactivated whole-virion hepatitis A vaccine, the first licensed vaccine against hepatitis A, was introduced in many countries worldwide, and a live attenuated vaccine became available in the People's Republic of China.
Immunogenicity of a thermally inactivated rotavirus vaccine in mice
TLDR
The results demonstrate the potential of heat inactivation as a novel approach to the manufacture of a safe and efficacious parenteral rotavirus vaccine, which should serve as an important addition to and back up for live oral rotav virus vaccine in children.
Epaxal®: a virosomal vaccine to prevent hepatitis A infection
  • P. Bovier
  • Biology, Medicine
    Expert review of vaccines
  • 2008
TLDR
This review summarizes all published papers on a virosome-formulated vaccine, Epaxal®, based on formalin inactivated HAV (strain RG-SB) adsorbed to the surface of special liposomes (virosomes), that replace aluminum hydroxide as the adjuvant principle.
Development of a new hydrogen peroxide–based vaccine platform
TLDR
It is demonstrated that H2O2-based vaccines are highly immunogenic, provide protection against a range of viral pathogens in mice and represent a promising new approach to future vaccine development.
Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains
TLDR
An overview of results from clinical trials with Sabin-IPV is given and the requirements and challenges in the clinical development of this novel IPV are discussed to achieve cost–prize reduction and improve affordability.
Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines
TLDR
The recent licensure of a Vero cell-derived live virus vaccine has coincided with an explosion in the development of a range of new viral vaccines, ranging from live-attenuated pediatric vaccines against rotavirus infections to inactivated whole-virus vaccines against H5N1 pandemic influenza.
Measles: old vaccines, new vaccines.
  • D. Griffin, C. Pan
  • Biology, Medicine
    Current topics in microbiology and immunology
  • 2009
TLDR
A live attenuated virus vaccine has been highly successful in protection from measles and in elimination of endemic measles virus transmission with the use of two doses.
...
1
2
3
4
5
...